[PDF][PDF] Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640
TS Heuer, R Ventura, J Lai, J Waszczuk - Cancer Res, 2016 - sagimet.com
TS Heuer, R Ventura, J Lai, J Waszczuk
Cancer Res, 2016•sagimet.comPreclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism
and efficacy of novel drug combinat Page 1 www.postersession.com Preclinical studies
characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel
drug combinations with TVB-2640 Timothy S. Heuer, Richard Ventura, Julie Lai, Joanna
Waszczuk, Kasia Mordec, Claudia Rubio, Glenn Hammonds, Marie O’ Farrell, Douglas Buckley
and George Kemble 3-V Biosciences, Menlo Park, CA Introduction Classification of Tumor …
and efficacy of novel drug combinat Page 1 www.postersession.com Preclinical studies
characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel
drug combinations with TVB-2640 Timothy S. Heuer, Richard Ventura, Julie Lai, Joanna
Waszczuk, Kasia Mordec, Claudia Rubio, Glenn Hammonds, Marie O’ Farrell, Douglas Buckley
and George Kemble 3-V Biosciences, Menlo Park, CA Introduction Classification of Tumor …
Classification of Tumor Lipogenic and Epithelial Gene Expression Aligns with FASN-Inhibitor Sensitivity In Vitro
sagimet.com
